- Madrigal's Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts🚀 Madrigal Pharmaceuticals' MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, accord…Endpoints · 2mo ago↗ source
- Former Orbital scientists launch new mRNA therapy startupTwo scientists think they've solved a technical problem that has kept the mRNA revolution from reaching its full potential. Now, they're launching ParcelBio with $13 million in seed funding to dev…Endpoints · 2mo ago↗ source
- Avalo scores Phase 2 success in comeback bid, raises $375MAvalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an exper…